Zydus Lifesciences gets USFDA nod for Leuprolide Acetate injection

Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative treatment of advanced prostatic cancer.

The approval by the US Food and Drug Administration (USFDA) is for Leuprolide Acetate injection of strengths 14 mg/2.8 ml (1 mg/0.2 mL) multiple-dose vial (reference listed drug Lupron Injection, 1 mg/0.2 mL), Zydus Lifesciences said in a regulatory filing.

The Leuprolide Acetate injections will be manufactured at the company’s oncology injectable manufacturing facility at SEZ1, Ahmedabad, it added.

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. It had annual sales of USD 69 million in the US, the company said citing IQVIA MAT September 2025 data.

Related Posts

Six Women Develop Serious Complications After C-Section

Jaipur/Kota — In a serious medical incident that has raised concerns over patient safety at government facilities, six women who underwent caesarean section deliveries at Kota’s New Medical College Hospital developed…

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Jaipur:  Continuing its statewide anti-adulteration and food safety enforcement drive, the Food Safety Department Rajasthan conducted a major inspection and sampling operation at a pharma biological manufacturing unit located in…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Six Women Develop Serious Complications After C-Section

Six Women Develop Serious Complications After C-Section

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Indian Pharma Majors Plan to Invest in US

Indian Pharma Majors Plan to Invest in US

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental